Literature DB >> 23742760

Prion formation correlates with activation of translation-regulating protein 4E-BP and neuronal transcription factor Elk1.

Elin K Allard1, Mirjana Grujic, Gilberto Fisone, Krister Kristensson.   

Abstract

Cellular mechanisms play a role in conversion of the normal prion protein PrP(C) to the disease-associated protein PrP(Sc). The cells provide not only PrP(C), but also still largely undefined factors required for efficient prion replication. Previously, we have observed that interference with ERK and p38-JNK MAP kinase pathways has opposing effects on the formation of prions indicating that the process is regulated by a balance in intracellualar signaling pathways. In order to obtain a "flow-chart" of such pathways, we here studied the activation of MEK/ERK and mTORC1 downstream targets in relation to PrP(Sc) accumulation in GT1-1 cells infected with the RML or 22L prion strains. We show that inhibition of mTORC1 with rapamycin causes a reduction of PrP(Sc) accumulation at similar low levels as seen when the interaction between the translation initiation factors eIF4E and eIF4G downstream mTORC1 is inhibited using 4EGI-1. No effect is seen following the inhibition of molecules (S6K1 and Mnk1) that links MEK/ERK signaling to mTORC1-mediated control of translation. Instead, stimulation (high [KCl] or [serum]) or inhibition (MEK-inhibitor) of prion formation is associated with increased or decreased phosphorylation of the neuronal transcription factor Elk1, respectively. This study shows that prion formation can be modulated by translational initiating factors, and suggests that MEK/ERK signaling plays a role in the conversion of PrP(C) to PrP(Sc) via an Elk1-mediated transcriptional control. Altogether, our studies indicate that prion protein conversion is under the control of intracellular signals, which hypothetically, under certain conditions may elicit irreversible responses leading to progressive neurodegenerative diseases.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  4E-BP; BDNF; BrdU; CGP 57380; DMSO; ERK; GT1-1 cells; Infections; Intracellular signaling; MAP; MAP kinase-interacting kinases; MEK; MEK-inhibitor (1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto) butadiene ethanolate); Mnk1-inhibitor N3-(4-fluorophenyl)-1h-pyrazolo[3,4-d]pyrimidine-3,4-diamine; Mnk1/2; Nervous system; Neurodegenerative diseases; PF-4708671; PrP(C); PrP(Sc); Prions; S6K1; S6K1-inhibitor 2-((4-(5-ethylpyrimidin-4-yl)piperazin-1-yl)methyl)-5-(trifluoromethyl)-1H-benzo[d]imidazole; S6rp; TSC; U0126; brain-derived neurotrophic factor; bromodeoxiuridine; dimethyl sulfoxide; disease-associated prion protein; eIF4E; eukaryotic initiation factor 4E; eukaryotic initiation factor 4E binding protein; extracellular signal-regulated kinase; immortalized hypothalamic gonadotropin-releasing hormone neurons; leupeptin; leupeptin hydrochloride; mTORC1; mammalian target of rapamycin complex 1; mitogen-activated protein; mitogen-activated protein kinase kinase; normal cellular prion protein; p70 ribosomal S6 Kinase 1; ribosomal protein S6; tuberous sclerosis complex

Mesh:

Substances:

Year:  2013        PMID: 23742760     DOI: 10.1016/j.nbd.2013.05.014

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  7 in total

1.  Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1.

Authors:  Naotaka Sekiyama; Haribabu Arthanari; Evangelos Papadopoulos; Ricard A Rodriguez-Mias; Gerhard Wagner; Mélissa Léger-Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

2.  Second messengers mediating the expression of neuroplasticity in a model of chronic pain in the rat.

Authors:  Luiz F Ferrari; Oliver Bogen; Jon D Levine
Journal:  J Pain       Date:  2014-01-07       Impact factor: 5.820

3.  Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G.

Authors:  Evangelos Papadopoulos; Simon Jenni; Eihab Kabha; Khuloud J Takrouri; Tingfang Yi; Nicola Salvi; Rafael E Luna; Evripidis Gavathiotis; Poornachandran Mahalingam; Haribabu Arthanari; Ricard Rodriguez-Mias; Revital Yefidoff-Freedman; Bertal H Aktas; Michael Chorev; Jose A Halperin; Gerhard Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-21       Impact factor: 11.205

4.  NMDA Receptor and L-Type Calcium Channel Modulate Prion Formation.

Authors:  Marco Zattoni; Chiara Garrovo; Elena Xerxa; Giada Spigolon; Gilberto Fisone; Krister Kristensson; Giuseppe Legname
Journal:  Cell Mol Neurobiol       Date:  2020-04-01       Impact factor: 5.046

5.  Strain-Dependent Effect of Macroautophagy on Abnormally Folded Prion Protein Degradation in Infected Neuronal Cells.

Authors:  Daisuke Ishibashi; Takujiro Homma; Takehiro Nakagaki; Takayuki Fuse; Kazunori Sano; Hanae Takatsuki; Ryuichiro Atarashi; Noriyuki Nishida
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

6.  Development of kinomic analyses to identify dysregulated signaling pathways in cells expressing cytoplasmic PrP.

Authors:  Rory H Shott; Cathy Appanah; Catherine Grenier; Guillaume Tremblay; Xavier Roucou; Luis M Schang
Journal:  Virol J       Date:  2014-10-03       Impact factor: 4.099

7.  The Priority position paper: Protecting Europe's food chain from prions.

Authors:  Jesús R Requena; Krister Kristensson; Carsten Korth; Chiara Zurzolo; Marion Simmons; Patricia Aguilar-Calvo; Adriano Aguzzi; Olivier Andreoletti; Sylvie L Benestad; Reinhard Böhm; Karen Brown; Byron Calgua; José Antonio Del Río; Juan Carlos Espinosa; Rosina Girones; Sue Godsave; Ludwig E Hoelzle; Michael R Knittler; Franziska Kuhn; Giuseppe Legname; Paul Laeven; Neil Mabbott; Eva Mitrova; Andreas Müller-Schiffmann; Mario Nuvolone; Peter J Peters; Alex Raeber; Klaus Roth; Matthias Schmitz; Björn Schroeder; Tiziana Sonati; Lothar Stitz; Albert Taraboulos; Juan María Torres; Zheng-Xin Yan; Inga Zerr
Journal:  Prion       Date:  2016-05-03       Impact factor: 3.931

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.